SERPINF1 and breast neoplasm: When combined with the frontline anti-bone-resorption drug zoledronic acid, PEDF reduced breast tumour metastasis to the bone, and was intriguingly able to preserve the quality of bone better than the combination therapy in a breast tumour model.